A preclinical perspective on the enhanced vulnerability to Alzheimer's disease after early-life stress

Hoeijmakers, L.; Lesuis, S.L.; Krugers, H.; Lucassen, P. J.; Korosi, A.

DOI
10.1016/j.ynstr.2018.02.003

Publication date
2018

Document Version
Final published version

Published in
Neurobiology of Stress

License
CC BY-NC-ND

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
A preclinical perspective on the enhanced vulnerability to Alzheimer's disease after early-life stress

Lianne Hoeijmakers, Sylvie L. Lesuis, Harm Krugers, Paul J. Lucassen, Aniko Korosi∗

Brain Plasticity Group, Center for Neuroscience, Swammerdam Institute for Life Sciences, University of Amsterdam, Science Park 904, Amsterdam, The Netherlands

A B S T R A C T

Stress experienced early in life (ES), in the form of childhood maltreatment, maternal neglect or trauma, enhances the risk for cognitive decline in later life. Several epidemiological studies have now shown that environmental and adult life style factors influence AD incidence or age-of-onset and early-life environmental conditions have attracted attention in this respect. There is now emerging interest in understanding whether ES impacts the risk to develop age-related neurodegenerative disorders, and their severity, such as in Alzheimer's disease (AD), which is characterized by cognitive decline and extensive (hippocampal) neuropathology. While this might be relevant for the identification of individuals at risk and preventive strategies, this topic and its possible underlying mechanisms have been poorly studied to date. In this review, we discuss the role of ES in modulating AD risk and progression, primarily from a preclinical perspective. We focus on the possible involvement of stress-related, neuro-inflammatory and metabolic factors in mediating ES-induced effects on later neuropathology and the associated impairments in neuroplasticity. The available studies suggest that the age of onset and progression of AD-related neuropathology and cognitive decline can be affected by ES, and may aggravate the progression of AD neuropathology. These relevant changes in AD pathology after ES exposure in animal models call for future clinical studies to elucidate whether stress exposure during the early-life period in humans modulates later vulnerability for AD.

1. Introduction

Alzheimer's disease is the most prevalent neurodegenerative disease among elderly and a major burden to society (Prince et al., 2013; Wimo et al., 2013). AD patients are characterized by progressive cognitive decline, that starts with mild cognitive impairments (MCI) and develops over time in full blown dementia. The brains of AD patients are characterized by the abundant presence of amyloid plaques, that are located extracellularly and contain various β-amyloid (Aβ) peptides, and by neurofibrillary tangles that are made up of hyper-phosphorylated tau inside of neurons (Querfurth and LaFerla, 2010; Scheltens et al., 2016). Neurodegeneration in the hippocampus, as the results of these neuro-pathological changes, is one of the key features of AD and in concert to the hippocampal other brain regions involved in the medial temporal lobe memory circuit are affected too (Weiner et al., 2015).

A small percentage of the demented population suffers from familial AD, in which the disease results from genetic mutations and/or specific gene variants. For the majority of patients with sporadic, late-onset AD, however, no genetic or heritable causes have been identified. These patients have been reported to show a high degree of heterogeneity in the progress of clinical symptoms, hippocampal plasticity and neuro-pathological characteristics (Komarova and Thalhauser, 2011; Mufson et al., 2015; Weiner et al., 2015). It is suggested that the etiology of sporadic AD relates to an interaction of specific genetic risk variants with various environmental and lifestyle factors, potentially leading to a dysregulated epigenome (Andrieu et al., 2015; Gatz et al., 2006; Haaksma et al., 2017; Maloney and Lahiri, 2016).

One of these environmental factors is stress. The frequency of lifetime distress has repeatedly been associated with accelerated cognitive decline, enhanced incidence of MCI and increased risk for late-onset AD (Aggarwal et al., 2014; Johansson et al., 2014; Sindi et al., 2016; Wilson et al., 2006, 2003; 2007). Particularly stress occurring during the sensitive period of early-life may additionally aggravate the later vulnerability to AD (Lahiri and Maloney, 2012, 2010). Individuals with a history of early-life stress (ES) have been shown to age less “successful” (Kok et al., 2017) and have an increased probability to develop diseases in old age (Dong et al., 2004; Ferraro et al., 2016; Schafer and Ferraro, 2012). Interestingly, the occurrence of parental death between the age...
of 0 and 18 years has been associated with a higher risk for AD (Norton et al., 2011; Ravona-Springer et al., 2012). Also, childhood neglect and traumatic events have been associated with an augmented risk to develop early MCI with age (Wang et al., 2016a) and childhood stress have been associated with dementia and AD in Australian aboriginals (Radford et al., 2017). On the other hand, early-life adversity was not associated with aging-related cognitive decline in Caucasians, and may even be protective against cognitive decline in an aging African American population (Barnes et al., 2012). Importantly, these retrospective studies may contain bias as the variation in the later-life decline and AD development. Notably, various specific AD characteristics are modeled in mice, i.e. by transgenic (over) expression of mutant genetic variants that underlie familial AD (Box 1). These transgenic models develop transgene driven AD-related neuropathological features such as amyloid plaques, and portray at least some of the associated cognitive deficits. This provides a useful approach to study whether and how risk factors, like ES, can modulate later pathological hallmarks, cognitive decline and related impairments in neuroplasticity.

Here, we discuss whether stress in early-life acts as a vulnerability factor for AD. We summarize the available pre-clinical literature and focus on the biological substrates that might mediate such vulnerability. Finally, we highlight the outstanding questions that can help bring the field forward.

2. Early-life experiences affect AD neuropathological hallmarks and cognition

In recent years, the vulnerability to develop AD after ES was investigated with the use of different ES rodent models (Box 2). These studies demonstrate that both positive and adverse early-life experiences can modulate disease severity and AD pathology (Cañete et al., 2015; Hoeijmakers et al., 2017; Hui et al., 2017; Lesuis et al., 2016, 2017; Martisova et al., 2012, 2013; Sierksma et al., 2012, 2013; Solas et al., 2010, 2013).

Interestingly, ES triggered Aβ formation in non-transgenic rats; MS from P2 to P21 induced an elevated ratio of the amyloid precursor protein (APP)-derived fragments C99 and C83, and an increased expression of Aβ40 and Aβ42 peptides in the hippocampus of adult (Martisova et al., 2012, 2013; Solas et al., 2010, 2013) and aged rats (Solas et al., 2010). While it is interesting to learn that ES enhances amyloidogenic processing in the brain of wild type rodents, these rats do not develop the pathological oligomeric or fibril forms of Aβ. ES experiments performed in transgenic AD models that do express these pathological Aβ species help to uncover if ES advances or accelerates these specific features of AD pathology with age.

Perinatal stress was shown to affect the later development of amyloid neuropathology in transgenic AD models in an age- and thus intrinsically pathological stage-dependent manner. In fact, both prenatal maternal-restraint stress (PS) from embryonic day (E)1 to E7 as well as chronic ES from postnatal day (P)P2-P9 reduced Aβ in the hippocampus of 4-month-old APPswe/PS1dE9 mice, a relatively early pathological stage. Specifically, Aβ plaque load in the hippocampus of female, but not male, APPswe/PS1dE9 mice was decreased after PS, while no effects were found on intracellular Aβ immunoreactivity, nor on hippocampal soluble Aβ40 and Aβ42 peptide levels (Sierksma et al., 2012, 2013). Chronic ES from P2 to P9 also reduced intraneuronal Aβ levels in the dentate gyrus of male APPswe/PS1dE9 mice (Hoeijmakers et al., 2017). On the other hand, 4-month-old bigenic (BiAT) mice, which express both amyloid and tau mutant genes, exposed to the same chronic ES design showed an elevation of Aβ peptide levels (Lesuis et al., 2016). Interestingly, at a later pathological stage in 9- and 10-month-old APPswe/PS1dE9 mice, hippocampal plaque load was aggravated after exposure to chronic ES from P2-P9 or after 3 weeks of MS (Hoeijmakers et al., 2017; Hui et al., 2017), while cortical plaque load was affected by MS at this age as well (Hui et al., 2017). This shows that although in some models Aβ is initially reduced in young adulthood, the pathology is exacerbated by ES exposure at later ages.

In contrast to the modulation of Aβ peptides, tau pathology received very little attention in ES studies so far. Interestingly, tau protein in the hippocampus undergoes specific isoform switches and phosphorylation
changes during the early-life period, which have been suggested to contribute to neuronal development and function (Sennvik et al., 2007; Boekhoorn et al., 2006). Although interference of such processes by stress in early-life can potentially have detrimental impact, based on the only study available on this topic to date, ES does not seem to impact phosphorylated tau in 4-month-old BiAT mice (Lesuis et al., 2016). At 4 months of age, BiAT mice do however not normally develop tau pathology, possibly preventing detection of any ES modulation in this study and highlighting the need for future investigation on the topic.

Interestingly, ES exposure also seemed to affect the cognitive performance of APPswe/PS1dE9 mice. The reduced Aβ plaque load in PS-exposed APPswe/PS1dE9 mice at 4 months and the MS-induced increased Aβ plaque load in the same transgenic mice at 9 months were associated with, respectively, improved and impaired performance in hippocampus-dependent cognitive tasks (Hui et al., 2017; Sierksma et al., 2013). Such ES-induced cognitive modulation was not detected in 4-month-old BiAT mice as both control and ES-exposed BiAT mice were unimpaired at this age (Lesuis et al., 2016).

In contrast to ES, and in support of the important role for the (quality of the) early-life environment, a ‘positive’ early-life experience attenuated Aβ pathology and cognitive decline. For instance, early handling (EH) from P2 to P9, which was associated with improved care by the mother, reduced Aβ levels in 4-month-old BiAT mice and in 11-month-old APPswe/PS1dE9 mice (Lesuis et al., 2016, 2017). This reduction in amyloid levels in APPswe/PS1dE9 mice after EH was further accompanied by an improved cognitive performance at 11 months of age (Lesuis et al., 2017). In addition, prolonged EH exposure from P1 to P21 prevented spatial learning impairments at a pre-pathological stage, in 4-month-old male and female 3xTgAD mice (Cañete et al., 2015).

These initial studies strongly suggest that perinatal experiences can shape the later progression of Aβ neuropathology and cognitive performance. In general, it appears as if stress experienced in early-life reduces Aβ pathological hallmarks at an early pathological stage, while it ultimately aggravates Aβ pathology at more advanced pathological stages. These alterations are associated with parallel changes in cognition. So far, these conclusions are based on only a few studies, which focus on Aβ rather than on tau neuropathology. This highlights the need to extend our knowledge of the consequences of ES at different pathological stages. Moreover, with the exception of the EH study in APPswe/PS1dE9 mice (Lesuis et al., 2017), these studies addressed cognition only in transgenic mice and not in age-matched wild type mice exposed to the early-life paradigm (Cañete et al., 2015; Hui et al., 2017; Sierksma et al., 2013). The inclusion of these control groups would be relevant in order to assess whether AD pathology accelerates or aggravates the onset of cognitive impairments relative to unstressed transgenic as well as stressed wild type groups. It is also important to understand which mechanisms are involved and which pathways might mediate such late consequences. This is addressed in the following sections.

3. Stress in early-life modulates regulators of Aβ and tau neuropathological progression

So far, most of the aforementioned ES studies have not fully addressed the possible mechanisms mediating the later neuropathological changes. It is interesting to speculate whether mechanisms involved in the effects of adult stress on AD neuropathology might also be important to consider in the context of early-life experiences. In fact, the impact of adult stress exposure on Aβ and tau hallmarks has been more extensively studied in various AD models (Machado et al., 2014; Marcello et al., 2015).

Overall, there are several pathways in which stress exposure can regulate Aβ progression. These include; 1) driving Aβ synthesis via the modulation of APP expression and the APP-cleaving secretases, or 2) by modulating clearance of Aβ, for instance by changes in transportation to the periphery or by altering the rate of phagocytosis by immune cells (Chesser et al., 2013; Deane et al., 2009; Martin et al., 2013; Ries and Sastre, 2016). The propagation of tau neuropathology on the other hand, is similarly modulated by tau expression, tau mutations, and activity of specific kinases and phosphatases. These factors are driving tau neuropathology and also ‘prion-like’ tau propagation is of relevance in this respect (Sanders et al., 2014). Alternatively, tau can be cleared through degradation pathways, halting the progression of pathology. We will here discuss the existing literature on these proposed regulators of AD neuropathology following (early-life) stress exposure.

3.1. Stress-related factors modulate AD neuropathology

Stress-related factors are certainly important to consider as possible modulators of AD pathology. Not only were stress hormone levels shown to be dysregulated in AD patients (Arsenault-Lapiere et al., 2010; Cernansky et al., 2006), but stress was also associated with an acceleration of the course and duration of MCI and with AD progression in general (Johansson et al., 2014; Sindl et al., 2016; Wilson et al., 2007). This effect is mostly thought to be mediated by stress-related hormones and neuropeptides, such as glucocorticoids (cortisol in human and corticosterone in rodents) and corticotropin releasing hormone/factor (CRH; CRF). Interestingly, ES exposure has been described...
to alter later hypothalamic pituitary adrenal (HPA) axis functioning, leading to an increased responsiveness to stressors and overexposing body and brain to elevated levels of glucocorticoids (reviewed in Frodl and O'Keane, 2013; Heim and Nemeroff, 2001). Such changes in HPA axis functioning could be considered a plausible mediator of accelerated AD pathology (Herbert and Lucassen, 2016).

### 3.1.1. Glucocorticoids

Various clinical studies have implicated elevated glucocorticoid levels in the cognitive decline that followed (cumulative life-time) stress experiences in elderly and AD patients (Arsenault-Lapierre et al., 2010; Comijs et al., 2010; Cernansky et al., 2006; Lupien et al., 1999; Popp et al., 2015). This supports an important role for glucocorticoids as possible mediators of AD vulnerability after exposure to stress and indeed several mechanistic, pre-clinical studies implicated glucocorticoids in the pathological processing of enhancing tau and amyloid levels after (adult) stress exposure (Baglietto-Vargas et al., 2015; Catania et al., 2009; Green et al., 2006; Joshi et al., 2012, 2013; Sotiropoulos et al., 2008, 2011).

As an example, glucocorticoid exposure and chronic stress in wild type rats enhanced phosphorylation of tau protein in the hippocampus and prefrontal cortex, likely through the elevated expression of kinases, and these alterations were associated with cognitive deficits in the rats (Sotiropoulos et al., 2011). Tau knockout mice further showed resilience for (part of) the stress-induced hippocampal abnormalities and cognitive deficits (Lopes et al., 2016), indicating a mechanism through which stress-induced tau alterations can enhance neuro-pathological hallmarks as well as vulnerability for cognitive deficits.

With respect to Aβ pathology, the expression of APP and the APP cleaving enzyme β-secretase 1 (BACE1) was increased by exposure to corticosterone or to the glucocorticoid receptor (GR) agonist dexamethasone, both in neuronal cell cultures as well as in 3xTgAD mice. These changes increased expression of APP-derived fragments (C99, C83), and notably, they further steered APP processing towards the amyloidogenic pathway, ultimately increasing Aβ levels (Green et al., 2006). A similar amyloidogenic potential of glucocorticoids was found after adult stress exposure, which also increased expression of BACE1 and APP-derived fragments in the hippocampus and frontal cortex of non-transgenic rats (Catania et al., 2009).

In addition, blocking the GR with the antagonist mifepristone attenuated both Aβ and tau pathology in 12-month-old 3xTgAD mice, after 3 weeks of treatment, while restoring cognitive performance in various behavioral tasks (Baglietto-Vargas et al., 2013). In contrast to the glucocorticoid-mediated elevation of Aβ, the neuropathological reduction after mifepristone treatment was not mediated by BACE1 activity, but through a still unknown APP protease that steered APP processing to the non-amyloidogenic pathway (Baglietto-Vargas et al., 2013).

Interestingly, ES modulated amyloidogenic pathways in non-transgenic rats via the same mediators as reported for adult stress and glucocorticoid exposure. BACE1 expression was elevated in MS-exposed, adult non-transgenic rats and accompanied by an increased C99/C83 ratio (Martisova et al., 2012, 2013; Solas et al., 2010, 2013). This elevated BACE1 expression was further associated with reduced DNA methylation of the BACE1 promoter (Martisova et al., 2012). On an additional note, the methylation levels of for example APP might also be instrumental in the processing of amyloid after ES, in a similar manner as discussed for BACE1 (Lahiri et al., 2009). It still remains to be determined when this epigenetic mark arises, but GR activity might possibly contribute to the induced BACE1 expression and DNA hypomethylation when considering that MS-exposed rats exhibit heightened corticosterone levels in adulthood (Aisa et al., 2007; Martisova et al., 2013). On the other hand, BACE1 DNA hypomethylation can also be a programmed epigenetic mark that arises directly after ES exposure and lasts into adulthood, and it will be interesting to study whether this or an ES-mediated rise in glucocorticoid levels and subsequent GR activation in adulthood affected methylation and the eventual BACE1 expression pattern. Chronic ES exposure did not induce an increase in basal corticosterone in adult mice (Naninck et al., 2015, 2017) and, thus, not all ES models induce elevated basal or stress-induced corticosterone levels. Whether glucocorticoid levels in chronic ES-exposed mice affect BACE1 expression, APP or other factors in the amyloid processing pathway to mediate the increased Aβ pathology in APPswe/PS1dE9 mice remains thus to be determined.

### 3.1.2. Corticotropin releasing factor/hormone

Next to glucocorticoids, clinical data have also pointed to abnormal CRF signaling in AD patients (De Souza et al., 1987; Hatzinger et al., 1995; May et al., 1987; Raadsheer et al., 1995). CRF levels were reported to be reduced in the cerebrospinal fluid and cortical tissue of (sporadic) AD patients (De Souza et al., 1987; May et al., 1987) and AD patients also responded less to stimulation of the HPA axis with exogenous CRF (Hatzinger et al., 1995). Next to this, CRF mRNA expression was elevated in postmortem tissue of the hypothalamic paraventricular nucleus of AD patients (Raadsheer et al., 1995). On the functional level however, CRF expression was reported to exert a neuroprotective response to Aβ toxicity (Pedersen et al., 2001) and to favor non-amyloidogenic APP cleavage (Lezoualc'h et al., 2000), which would both be beneficial in a context of Aβ accumulation.

In contrast to these observations, multiple studies have indicated that stress exposure aggravated Aβ neuro-pathology in close association with elevations in CRF. Enhanced CRF signaling in 3xTgAD mice subjected to chronic adult stress was associated with enhanced Aβ neuro-pathological progression (Baglietto-Vargas et al., 2015). Kang and colleagues have further shown that exogenous administration of CRF, but not corticosterone, mimiced the acute stress-induced increase in Aβ40 and Aβ42 (Kang et al., 2007), and central CRF administration similarly enhanced these peptide levels (Dong and Csernansky, 2009). Such an Aβ-enhancing potential of CRF can be mediated through γ-secretase activity, showing a mechanistic link between (stress-induced) CRF and Aβ (Park et al., 2015). In addition, the modulating role of CRF in stress-induced Aβ was confirmed by a deficiency in CRF signaling, either via a CRF receptor 1 (CRFR1) knockout line or antagonist treatment, respectively, showing a blockage of the stress-induced aggravation in Aβ pathology after post-traumatic stress-like exposure in APPswe/PS1M146V mice (Justice et al., 2015), and after acute stress in Tg2576 mice (Kang et al., 2007). Next to this, several studies have also attributed the potential of stress to enhance tau pathology to CRF (Carroll et al., 2011; Rissman et al., 2007). Tau phosphorylation was enhanced in CRF overexpressing mice compared to wild type mice and treatment with a CRFR1 antagonist restored the phosphorylation of tau to wild type levels at some but not all epitopes (Campbell et al., 2015). Adult stress exposure increased tau hyperphosphorylation through the activity of specific kinases mediated by CRFR1 activation (Rissman et al., 2007). Similar to adult stress, ES in rodents led to enhanced CRF signaling in the hippocampus (Ivy et al., 2010) and frontal cortex (Wang et al., 2011). This implicates that altered CRF signaling after ES exposure may contribute to AD-related tau hyperphosphorylation and Aβ aggravation, but further evidence is needed to test this hypothesis.

To summarize the role of (early-life) stress-related factors in the later vulnerability to develop AD, both glucocorticoids and CRF have been implicated in the progression of AD neuropathology. This supports the possibility that the enhanced AD vulnerability after ES might be mediated by the alterations in the stress system. Intervention studies that modulate the consequences of ES on stress signaling should help to clarify these cause-or-effect aspects and further elucidate this relationship. In addition, it will be interesting to investigate if ES has the potential to also (epigenetically) program expression of AD neuro-pathological modulators, such as tau, APP, or BACE1 expression, possibly via GR activation.
3.2. Regulation of the inflammatory response to amyloid neuropathology by ES

Over the recent years, attention for the role of neuroinflammation in AD etiology has strongly increased (Heneka et al., 2015; Mhatre et al., 2015; Wyss-Coray and Rogers, 2012). Clearance of Aβ can be mediated by microglia, the innate immune cells of the brain, and/or by infiltrating myeloid cells. The latter are still debated as to whether they just assist, or rather overtake microglial functions in AD (Bates et al., 2009; Fu et al., 2012; Hickman et al., 2008). The accumulation of Aβ in the brain has been shown to elicit a chronic inflammatory response, both in terms of microglial and complement activation (Rodríguez et al., 2010; Veerhuis et al., 2003; Zhang et al., 2012), depending on the pathological stage (Sudduth et al., 2013). The potential of neuroinflammatory modulation of AD progression was further illustrated by studies that change the neuroinflammatory response using genetic tools to, depending on the specific type of modulation, either aggravate (Griciu et al., 2013; Mass et al., 2017; Wang et al., 2015; Wang et al., 2016b) or ameliorate Aβ neuropathology (Guo et al., 2015; Hjorth et al., 2013; Lee et al., 2010).

Despite these relevant findings, a possible role for inflammation in the interaction between (early) stress and AD has so far been addressed only in a few studies. First, an adult stress-induced increase in plaque pathology in Tg2576 mice was found to coincide with a reduction in plaque-associated microglia (Carroll et al., 2011), indicating a reduced microglial response to Aβ deposits. A comparable reduction in plaque-associated Iba1 immunoreactivity, a marker for microglia, was observed in chronic ES-exposed 10-month-old APPswe/PS1dE9 mice (Hoeijmakers et al., 2017). However, an opposite phenotype was observed at an earlier age in the 4-month-old APPswe/PS1dE9 mice, since ES enhanced the expression of microglial CD68, a lysosomal protein and phagocytic marker in 4-month-old APPswe/PS1dE9 mice (Hoeijmakers et al., 2017).

One can speculate that the changes in neuropathology between 4 (reduced Aβ in ES group) and 10 months (increased Aβ in ES group) in the ES-exposed mice were not due to differences in Aβ production, but may rather result from a differential clearance mediated through microglia. An outstanding question in that respect is, whether the microglial response to inflammatory challenges like Aβ is intrinsically (epigenetically) programmed by ES in the microglia, and then evoked by Aβ exposure in adulthood. Other ES studies in rats have indeed shown that the microglial response in adulthood was primed or sensitized when stimulated by secondary inflammatory challenges, leading to an enhanced (pro-)inflammatory response from microglia (Diz-Chaves et al., 2012; Szcseny et al., 2014). On the other hand, other cell types, such as neurons and astrocytes, release factors that can regulate microglia and thereby modulate their inflammatory response. As an example, fractalkine signaling between neurons and microglia was found to be diminished in P5-exposed rats by the reduced expression of the (neuron-derived) chemokine CX3CL1 and the microglial CX3CR1 receptor (Ślusarczyk et al., 2016), indicating that neurons might influence the microglial phenotype after ES exposure.

Together, these data show that ES affects microglia and their neuroinflammatory responses, and that this in turn might modulate Aβ neuropathological progression. It still needs to be elucidated if an altered microglial phenotype after ES exposure might contribute to aggravated Aβ pathology in APPswe/PS1dE9 mice via a change in Aβ clearance. In addition, it will be important to further investigate if the microglial phenotype in ES APPswe/PS1dE9 mice results from an intrinsic, primed, or sensitized microglial response to Aβ. Alternatively, the Aβ accumulating in ES-exposed mice might have elicited impairments in other cell types in the brain, which may then stimulate the microglia to respond more or less strongly.

3.3. Metabolic factors can play a role in progression of AD neuropathology after ES

Other factors that can modulate AD vulnerability after ES exposure relate to the metabolic aspects of AD. Over the last years, the abnormal metabolic profile of AD patients (Bedse et al., 2015; Dineley et al., 2014) and the beneficial or aversive effects of nutrients on AD progression have received considerable attention (Luchsinger et al., 2007; Ramesh et al., 2010; Solfrizzi et al., 2017). In fact, a recent study also provided evidence that early-life nutritional deficiency during the Great Chinese famine elevated the incidence of MCI in later life (Kang et al., 2017) and it has been suggested that metabolic and nutritional factors during early-life might indeed modulate the onset and progression of cognitive decline and AD (Lahiri et al., 2007).

The topic of nutritional deficiency is of particular interest as improving eating habits represent a non-invasive and relatively cheap tool for intervention in order to prevent or delay AD. Adversities in early-life, and stress in particular, have been well-described to affect metabolism and the nutritional profile (reviewed in among others Lucassen et al., 2013; Yam et al., 2015). Such metabolic changes after ES included among others fat deposition and altered signaling of the fat-derivative leptin (Yam et al., 2017a), reduced insulin signaling (Solas et al., 2013), elevated cholesterol levels (Puternain et al., 2016) and altered polyunsaturated fatty acid plasma levels, including reduced omega-3 fatty acids (Clarke et al., 2009). We next discuss two of these important metabolic regulators, i.e. insulin signaling and fatty acid levels, that might contribute to AD neuropathological progression after exposure to ES.

3.3.1. Insulin resistance in AD

Hyperinsulinemia leads to a deficiency in insulin signaling, or insulin resistance, that can ultimately develop into type II diabetes. Type II diabetes is highly prevalent world-wide and a well-recognized risk factor that potentiates AD progression (Baker et al., 2011; Biessels et al., 2014; Steen et al., 2005). The involvement of insulin in AD progression was further demonstrated by studies of APP overexpression models that developed insulin resistance with age, and normalizing such abnormal signaling ameliorated cognitive deficits and Aβ peptide levels (Pedersen et al., 2006). But how could hyperinsulinemia promote AD progression? One of the mechanisms via which hyperinsulinemia has been suggested to promote Aβ accumulation is via the insulin-degrading enzyme (IDE) that degrades not only insulin, but also Aβ. An impairment in IDE might thus lead to both high insulin and Aβ levels, and because of the higher affinity for insulin, IDE might degrade less or even no Aβ peptides under conditions of high insulin (Qiu and Foltstein, 2006). Moreover, hyperinsulinemia has also been associated with AD vulnerability via other pathways, as discussed in various excellent reviews (Craft, 2005; Diehl et al., 2017; De la Monte, 2009).

Interestingly, both adult stress and ES have been shown to affect insulin levels and insulin signaling. The suppression of insulin signaling in 6-month-old APPswe/PS1dE9 mice was potentiated by exposure to chronic unpredictable mild adult stress and therewith aggravated the Aβ phenotype (Han et al., 2016). Amyloidogenic processing in PS-exposed adult non-transgenic rats was similarly accompanied by decreased expression of various factors involved in insulin signaling pathways (Solas et al., 2013). Together, these studies suggest that adult stress and ES can induce amyloidogenic processing through altered insulin signaling (Han et al., 2016; Solas et al., 2010). Furthermore, chronic ES exposure increased insulin levels in P9 mice (Yam et al., 2017b) as well as adult rats (Maniam et al., 2015), which is thus consistent with the concept that ES increases the risk for hyperinsulinemia and insulin resistance. Altogether, there is evidence for insulin-mediated AD hallmarks after ES exposure, but additional investigation to directly tackle the effect of ES-modulated insulin signaling in transgenic AD models are needed to gain insight into this topic.
3.3.2. Involvement of omega-3 and omega-6 fatty acid profiles in AD vulnerability

Research on the essential omega-3 and omega-6 fatty acids has implicated the omega-3 variant to be beneficial for brain functioning (Fiala et al., 2017; Zárate et al., 2017). Omega-3 supplementation or deficiency in adult rodents, indeed, altered progression of Aβ neuro-pathology and cognitive decline in different APP mutant mouse models (Calon et al., 2005; Green et al., 2007; Lim et al., 2005; Oksman et al., 2006). This makes these poly-unsaturated fatty acid levels another interesting factor with respect to AD vulnerability. Interestingly, ES reduced omega-3 fatty acids in the plasma of adult rats exposed to MS during early-life (Clarke et al., 2009). In addition, when MS-exposed rats were fed an omega-3 deficient diet throughout adulthood, these rats showed a higher vulnerability for metabolic deficits when compared to unsted rats fed with this deficient diet (Bernardi et al., 2013; Mathieu et al., 2008).

These studies thus suggest that the reduction in omega-3 fatty acids after ES can make ES-exposed mice more vulnerable to (progression of) AD neuropathology and cognitive decline. But how can fatty acids exert such modulatory effects on the brain? Dietary enrichment with omega-3 in adult unstressed mice showed that Aβ neuro-pathology was reduced in the cortex of 18-month-old Tg2576 mice after ± 3 months of dietary supplementation (Lim et al., 2005). This reduction could not be attributed to an altered expression of well-known drivers of the amyloidogenic pathway, including APP, BACE1, and ApoE (Lim et al., 2005). The beneficial effects of omega-3 fatty acids on Aβ accumulation seemed actually to be mediated by reduced PS1 expression and this was found to reduce γ-secretase activity, subsequent amyloidogenic processing and eventually even tau hyperphosphorylation in the 3xTgAD mice (Green et al., 2007). It still remains to be investigated if an ES-modulated omega-3 profile contributed to altered Aβ neuro-pathological progression. Next to this, it is of interest to mention that fatty acids can directly benefit other AD-related aspects, like neuroplasticity (Calon et al., 2004, 2005; Hashimoto et al., 2006), and inflammation (Hjorth et al., 2013), which might additionally contribute to the ES phenotype.

3.4. Interplay of the neuropathological regulators that are affected by ES

As discussed in the previous sections, AD might progress after ES exposure through the modulation of stress-related, neuroinflammatory and metabolic factors. Additional studies on the direct consequences of ES for each of these modulating pathways, at different time points in transgenic models of AD, should help to elucidate the determining factors. It must be noted in this respect that the different systems that can affect AD neuropathology after ES exposure are strongly inter-related and alterations in one system will likely elicit many changes in another. This makes it unlikely that ES would affect solely one of these systems while leaving others untouched (Hoeijmakers et al., 2015).

To further illustrate this subtle interplay between stress, neuroinflammation and metabolism, hyperinsulinaemia was for instance found to enhance central inflammation and Aβ42 levels in the cerebrospinal fluid of healthy adults (Fishel et al., 2005). In addition, Tg2576 mice developed Aβ pathology next to impaired insulin levels, that in turn can drive a rise in fasting-induced corticosterone and hyperinsulinaemia by 13 months of age (Pedersen and Flynn, 2004). This process could be prevented by modulating glucose and lipid metabolism through a dietary intervention, containing (among others) a peroxisome proliferator-activated receptor-γ (PPARγ) agonist (Pedersen and Flynn, 2004), that acts not only as a metabolic but also as an inflammatory mediator. Omega-3 fatty acids further modulated microglial phagocytosis of Aβ (Hjorth et al., 2013), while neuroinflammation is again regulated by stress mediators, like corticosterone (Espinos-Oliva et al., 2011; Frank et al., 2012; Tynan et al., 2010), that can in turn induce insulin resistance (van Donkelaar et al., 2014).

These studies portray the interrelated characteristics of several pathways related to ES as well as AD. The interactions of these different factors at play have unfortunately not been studied in detail in AD yet, but such studies might shed light on the primary modulating pathways of ES in determining AD vulnerability. This interrelated character obviously makes it also difficult to tease out whether ES determines AD vulnerability through one common denominator or driving factor, or whether a synergistic action of all these pathways is involved. This awaits future studies.

4. AD vulnerability through ES-modulated neuropasticity

Neuronal networks can be modified by selective pruning of synapses, formation of new, or strengthening of existing ones (Chatterji et al., 2015; Kim and Diamond, 2002; Martin et al., 2000). Next to this, the hippocampus exhibits the (unique) capacity to generate new, functional neurons, a process that was shown to be essential for hippocampus-dependent cognitive functioning (Kempermann et al., 2015; Leuen et al., 2006). Such neuronal plasticity forms are ultimately affected by the neuropathological progression in AD, as supported by the synapse loss, neuronal atrophy and selective cell death in the AD brain (Cramer and Flood, 1987; De Leon et al., 1997; Scheff et al., 1990), which is at least in part paralleled by pre-clinical research in rodent models of AD (for reviews, see Götz and Ittner, 2008; Götz et al., 2012; Jiang and Chung, 2016; Marlett and Lucassen, 2010; Pozueta et al., 2013; Selkoe, 2002). This close relation between pathology and neuroplasticity deficits as well as (aberrant) regenerative responses in AD (Kühn et al., 2001, 2007) makes it relevant to discuss how ES affects neuroplasticity in AD models.

Next to this, ES-exposed wild type rodents have been reported to display reduced levels of hippocampal neurogenesis at an adult age (Hulshof et al., 2011; Naninck et al., 2015; Oomen et al., 2015; Suri et al., 2013), decreased in dendritic complexity (Huo et al., 2002; Ivy et al., 2008), reduced spine density and synaptic protein expression (Aisa et al., 2009; Wang et al., 2011), as well as impaired long-term potentiation of synaptic connections (Brunson et al., 2005; Herpel et al., 2012; Ivy et al., 2008; Wang et al., 2011). Such impairments in neuroplasticity are thought to underline the cognitive deficits in ES-exposed adults, and these neuroplasticity forms as well as cognition decline with aging (Barnes et al., 1997; Foster, 2012; Lindner, 1997). Considering this, we first discuss how ES intrinsically affects such aging-related alterations in cognition and neuroplasticity in wild type rodents, followed by the evidence for neuroplasticity alterations in AD models after ES exposure.

4.1. ES modulation of neuroplasticity with aging

Interestingly, the regulators of the ES-mediated impairments in neuroplasticity in adult offspring can be attributed to stress signals, neuroinflammatory alterations and metabolic changes (for reviews see Hoeijmakers et al., 2015; Johnson and Kaffman, 2017; Korosi et al., 2012), implicating that similar pathways might be involved in stress-induced neuroplasticity changes in AD-related neuropathology. In addition, ES exposure in rodents was shown to induce several of the later-life (neuronal) consequences already early-on, lasting into adulthood, such as the ES-induced reduction in hippocampal volume in mice (Hoeijmakers et al., 2017; Naninck et al., 2015), whereas other consequences were actually age-dependent. As an example, chronic ES exposure in mice increased cell proliferation at P9, but reduced newborn cell survival in the adult hippocampus (Naninck et al., 2015). Although the consequences of ES have been extensively studied in adulthood, less attention has been given to how this phenotype is affected with aging.

With aging, the majority of elderly typically show a decline in cognition (Kirova et al., 2015; Langa and Levine, 2014) and cognitive functioning in rodents similarly diminishes with age (Barnes et al., 1997; Foster, 2012; Lindner, 1997). One can imagine that impairments
in the neuroplasticity after ES exposure can trigger a steeper decline with aging. Indeed, individuals with a history of childhood exhibited cognitive deficits already in (young) adulthood (Chugani et al., 2001; Kaplan et al., 2001; Mueller et al., 2010) and these deficits seem to further progress in a stronger manner with aging (Radford et al., 2017; Wang et al., 2016a).

In aged rodents, cognitive impairments were exacerbated in PS-exposed rats (Valle et al., 1999), and a similar phenotype was confirmed in aged rats that underwent MS from P2-14 (Sousa et al., 2014) or from P2-P21 (Solas et al., 2010). In comparison to age-matched control rats, MD on P3 similarly led to a more cognitively impaired aged rats, but in addition it also led to more good performers during the learning task (Ottil et al., 2000). This study thus indicated that ES did not impair all rats, but rather that the individual variation within the group was enhanced with aging after stress exposure early in life.

Altogether, the majority of these studies point to an aggravated age-related cognitive decline in ES-exposed rodents. Such impairments in cognitive performance were accompanied by impaired long-term potentiation in CA1-CA3 synapses of 16-month-old MS-exposed rats, when compared to age-matched controls (Sousa et al., 2014). A study of 30- to 32-month-old rats that were exposed to MD on P3 and classified as cognitively impaired or unimpaired, based on Morris water maze training in aging, revealed that 5-HT receptor 1 mRNA expression in the hippocampus was more strongly increased in impaired MD rats compared to the impaired control rats (Sibug et al., 2001). In addition, activity-regulated cytoskeleton-associated protein (ARC) mRNA expression, but not brain-derived neurotrophic factor (BDNF), was strongly reduced in aged rats with a history of MS, relative to unstressed aged rats and adult groups (Solas et al., 2013).

Other parameters of neuronal plasticity have, to our knowledge, so far not been studied in aged ES-exposed rodents and their age-matched controls. Nevertheless, based on the evidence for impaired cognitive performance of ES aged rats, it is to be expected that neuronal plasticity parameters will be impaired too. Additional studies are needed to further elucidate which factors are involved in the aggravated aging-related decline after ES.

4.2. ES might aggravate AD-related impairments in neuroplasticity

Next to a potential steeper decline with aging per se, it is plausible that ES exacerbates various neuroplasticity hallmarks in AD transgenic mouse lines. For example, dendritic complexity is altered by chronic ES in different brain regions of BiAT mice, with reduced complexity in the infralimbic frontal cortex and increased complexity in the prelimbic frontal cortex and amygdala (Lesuis et al., 2016). The expression of BDNF is reduced in the female, but not male hippocampus of PS-exposed APPswe/PS1dE9 mice relative to control APPswe/PS1dE9 (Sierksma et al., 2012). Both these studies of BiAT and APPswe/PS1dE9 were performed in 4-month-old mice, an age when no cognitive deficits are yet present. It will therefore be of particular interest to study the alterations in neuroplasticity also at an age when cognitive functioning of ES transgenic mice differs from control transgenic mice, such as for 9-month-old ES APPswe/PS1dE9. Interestingly, these 9-month-old ES-exposed APPswe/PS1dE9 mice showed an increased loss of cholinergic neurons in their forebrain, in close association with memory deficits (Hui et al., 2017). These 3 studies together indicate that neuroplasticity appears to be reduced by ES in AD transgenic mouse models.

Unfortunately, all 3 studies failed to include wild type littermates that are exposed to the same early-life paradigms. This hampers the possibility to address whether the ES phenotype is different or aggravated in mice with a transgenic background. Previous studies subjecting wild type mice to the same stress paradigms showed that at least prefrontal cortex dendritic arborization (Yang et al., 2015) and BDNF expression (Dong et al., 2015; Zheng et al., 2016) were similarly affected by chronic ES and PS. It is, therefore, at this point unclear if neuroplasticity markers in these studies are differently or more strongly affected when ES is applied in mutant APP mice when compared to wild type mice.

Several studies on chronic stress at an adult age interestingly point to a steeper decline in neuroplasticity hallmarks in AD transgenic models than in non-stressed transgenic or stressed wild type mice (Baglietto-Vargas et al., 2015; Grigoryan et al., 2014). Spine numbers in the stratum radiatum and stratum lacunosum moleculare of the CA are reduced by adult stress exposure in wild type mice, but more strongly so in the 3xTgAD mice (Baglietto-Vargas et al., 2015). When compared to wild type and control 3xTgAD mice, 6-month-old stress-exposed 3xTgAD mice additionally exhibited a stronger decrease in long-term potentiation, as was recorded in the CA1 stratum radiatum (Grigoryan et al., 2014). These studies suggest that adult stress can modulate neuroplasticity factors that in turn may accelerate impairments, either as a result of a faster progression of neuropathology, or by direct effects of adult stress regulation and stress hormone exposure on neuronal functioning.

To conclude, neuroplasticity seems to be impaired in ES-exposed AD transgenic mice compared to non-stressed transgenic mice. Such impairment appears in line with the stronger cognitive decline in ES-exposed AD transgenic mice, however, it remains unclear whether this impairment is similar for ES wild type and ES AD transgenic mice, or whether the neuroplasticity impairments are stronger in the transgenic models exposed to ES. To address this question, it is essential that future studies include both ES-exposed transgenic mice as well as wild type mice, and compare those to the unstressed transgenic and wild type controls. In addition, other synaptic plasticity-related molecules than those studied to date might be interesting future targets. As examples, ES has been reported to impact neural cell adhesion molecules (NCAMs; Aisa et al., 2009; Marco et al., 2013), polysialylated (PSA-)NCAM (Castillo-Gómez et al., 2017; Tsoory et al., 2008) and nectin-3 levels (Wang et al., 2013), which are also associated with AD-related neuropathological impairments (Leshchynska et al., 2015; Maurin et al., 2013; Mikkonen et al., 1999). It will furthermore be of interest to investigate if the neuroplasticity impairments result from an altered progression of the neuropathology in the transgenic lines, or if these changes occur irrespective of neuropathology.

5. Development of AD through ES-mediated later-life risk factors

Next to ES-induced cognitive deficits in adulthood (Chugani et al., 2001; Kaplan et al., 2001; Mueller et al., 2010), childhood stress has been indicated to enhance the risk for other later-life adversities. The risk to experience later-life trauma or other adult stressful events was indeed enhanced in individuals with an ES history (Dich et al., 2015) and also the risk to develop psychopathologies in adulthood was associated with an ES history (McLaughlin et al., 2010). This feature brings forward another interesting aspect through which ES can potentially regulate AD vulnerability. Multiple recognized adult risk factors for AD were shown to be determined by ES, and these include but are not limited to a cumulative stress or allostatic (over)load (Barboza Solís et al., 2015; Bellis et al., 2015; McLaughlin et al., 2010; Tomasdottir et al., 2015), obesity (Barboza Solís et al., 2015; Ferraro et al., 2016) and depression (Hovens et al., 2012; Miller and Cole, 2012; Turner and Butler, 2003). ES might in this way be the first step to comorbidity as a cumulative factor increasing vulnerability for AD.

Given these later-life risk factors and the reduced cognitive functioning of ES-exposed individuals, it can be questioned whether also the ‘cognitive reserve’ of ES-exposed individuals is lower. Cognitive reserve can be seen as someone’s ability to cope with emerging damage in the brain, until a certain threshold is reached and the loss of function becomes apparent (Stern, 2002). Also in AD patients, neuropathological hallmarks have been accumulating in the brain for many decades before the first clinical signs of AD arise as the manifestation of MCI (Jack et al., 2010, 2013). This suggests that individuals with lower cognitive abilities or less neuroplasticity capacities could be classified as having a
lower cognitive reserve and might exhibit, irrespective of the neuropathological build-up, an earlier onset of MCI and AD.

Several studies indeed showed that the onset of AD was earlier and progressed stronger in individuals with lower intellectual and cognitive abilities (Osone et al., 2014; Pietrzak et al., 2015; van Veluw et al., 2012). In addition, the cognitive abilities at age 11 were associated with the cognitive level of 79-year-old non-demented elderly (Gow et al., 2008), indicating that childhood cognition may indeed be associated with cognition during aging. However, the decline of these non-demented elderly between age 79 and 83 was not associated with their childhood abilities (Gow et al., 2008), suggesting that the decline in aging was not related with childhood performance. Indeed, a large (prospective) study of Danish men (Olsen et al., 2017) and a Scottish cohort (McGurn et al., 2008) associated lower cognitive abilities specifically with an increased risk for (vascular) dementia, and not AD, although the number of AD patients in these studies was very low. On a similar note, a higher social economic household was associated with higher cognitive abilities that were retained during aging, but neither higher nor lower social economic household were an indicator for AD aging was not related with childhood performance. Indeed, a large (prospective) study of Danish men (Olsen et al., 2017) and a Scottish cohort (McGurn et al., 2008) associated lower cognitive abilities specifically with an increased risk for (vascular) dementia, and not AD, although the number of AD patients in these studies was very low. On a similar note, a higher social economic household was associated with higher cognitive abilities that were retained during aging, but neither higher nor lower social economic household were an indicator for AD development (Wilson et al., 2005).

On an additional note, there is current interest in the potentially transgenerational effects of ES. Several reports have provided evidence for inheritable effects across generations for at least some of the ES consequences, mediated by DNA methylation or other epigenetic mechanisms (Bohacek and Mansuy, 2015; Franklin et al., 2010; Gapp et al., 2014; Roth et al., 2009). The hypothetical latent early life associated regulation (LEARn) model furthermore proposes that later-life disease, such as sporadic AD, develops faster in individuals who might have inherited specific (epi)genetic trait and experienced an adverse, environmental early-life event (Lahiri et al., 2009; Maloney and Lahiri, 2016). Transgenerational effects of (early-life) stress might in such a way lead to higher risk for dementia in a heritable fashion.

Overall, the discussed studies show that childhood cognition is intrinsically associated with specific forms of dementia, while cognitive abilities in adulthood were specifically associated with a risk for AD. It will be of interest to further explore how general cognitive abilities throughout life determine AD risk and whether indeed a lower cognitive reserve will lead to an earlier onset of MCI and AD.

6. Mediators of ES vulnerability for AD; a model

The ES phenotype is suggested to be determined by the interplay of different systems (Hoeijmakers et al., 2015) and it is of interest that these same systems are implicated in neuroplasticity regulation and in the progression of AD neuropathology. We propose the following model of ES-mediated vulnerability for AD (Fig. 1). We hypothesize that ES modulates the inflammatory, stress and/or metabolic systems. The interplay of these systems will lead to aggravated AD-related neuro-pathology, which in turn can reduce hallmarks of neuroplasticity, such as synaptic connectivity and hippocampal neurogenesis, to ultimately diminished cognitive abilities. Alternatively, ES directly reduces neuroplasticity and its associated cognitive functions through inflammatory, stress and metabolic regulation as well, and may thereby potentially lower the cognitive reserve of ES individuals. Finally, ES is an important risk factor for the occurrence of later-life stress events and such cumulative stress again would induce a cumulative risk for deficits through the aforementioned pathways.

7. Conclusion

Childhood stress experiences are suggested to modify various aspects of healthy aging and the development of AD. The decades-long interval between such early-life experiences and the onset of aging-related diseases like AD is problematic for (prospective) studies on the association between ES exposure and AD vulnerability. A thorough discussion of the pre-clinical research on this topic is therefore crucial to improve our understanding of the topic. The studies on rodent models support a modulatory effect of stress experienced in early-life in Fig. 1. Proposed model of how exposure to early-life stress could modify Alzheimer’s disease vulnerability.

Early-life stress (ES) alters, either directly or through an enhanced sensitivity to later-life stress effects, neuroinflammatory, stress and metabolic regulation. Several potential candidate factors involved in such regulation have thus far been identified to alter AD-related amyloid and tau pathological hallmarks and may therewith reduce neuroplasticity. These 3 systems can additionally impact neuroplasticity, irrespective of the development of AD neuro-pathology. Ultimately, the reduced neuroplasticity during this period may result in a lower cognitive reserve and finally in an earlier and possible more aggressive cognitive decline. These closely interrelated events may altogether determine AD vulnerability after exposure to stress in early-life.
the progression of AD. Preclinical research has, however, not fully explored which factors are involved in this relation, and more controlled preclinical studies are thus essential to identify these factors, to unravel their interactions and to verify the current findings (Box 3). Such knowledge, supported by (prospective) clinical studies, will strongly benefit the identification of populations at elevated risk for AD, which can possibly allow to develop an early and targeted treatment during the many decades between ES exposure and AD (clinical) onset.

Funding

This work was supported by Alzheimer Nederland (AN) (WE-03-2012-41) and Internationale Stichting Alzheimer Onderzoek (ISAO; grant numbers 12536 and 12534).

References


immunity of patients with Alzheimer's disease by omega-3 fatty acids. Faseb. J. 31,
81, 107.

Effects of stress and stress hormones on amyloid-β protein and plaque deposition.

Brain-derived neurotrophic factor epigenetic modifications associated with schizo-
phrenia-like phenotype induced by prenatal stress in mice. Biol. Psychiatry. 77,

934–937.

Espinosa-Oliva, A.M., de Pablos, R.M., Villarín, R.F., Argüelles, S., Venero, J.L., Machado,
A., Cano, J., 2011. Stress is critical for LPS-induced activation of microglia and damage
neurobiolaging.2010.01.012.


Fiala, W., Koził, G., Wagner, K., Hammock, B., Pellegrini, M., 2017. Modulation of innate
immunity of patients with Alzheimer's disease by omega-3 fatty acids. Faseb. J. 31,

Fishel, M., Wann, M.D., Huseman, T.E., Wang, Q., Qu, G., Zhao, Y., Kuslart, J.J., Cook, D.G.,
Peppard, E.R., Baker, L.D., Goldberg, D., Nie, W., Anstaha, S., Pymate, S.R., Schwartz,
M.W., Craft, S., 2005. Hyperinsulinemia provokes synchronous increases in central

Foster, T.C., 2012. Dissecting the age-related decline on spatial learning and memory
tasks in rodent models: N-methyl-D-aspartate receptors and voltage-dependent Ca2+
doi.org/10.1016/j.pneurobio.2012.01.007.


Lindner, M.D., 1997. Reliability, distribution, and validity of age-related cognitive deficits
s0135091.


